A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)
Latest Information Update: 08 Jul 2019
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Heartburn
- Focus Therapeutic Use
- Sponsors Takeda
- 27 Mar 2018 Status changed from recruiting to completed.
- 26 Jan 2017 Status changed from not yet recruiting to recruiting.
- 23 Aug 2016 New trial record